European Society for Radiotherapy and Oncology (ESTRO) shared a post on LinkedIn:
“Five-year outcomes from the hypo-FLAME trial, acute toxicity results from the PACE-C trial, and key findings from the STORM trial were revealed at ESTRO24. Learn how SBRT is advancing treatment and improving outcomes in prostate cancer.”
Read further.
Source: ESTRO/LinkedIn
More posts featuring ESTRO24 on oncodaily.com